US › Healthcare

Immuron Ltd ADR (IMRN)

US · Healthcare · Biotechnology

$1.08+1.89%

Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue

$4.1M

Revenue YoY

+105.7%

Net profit

$-1.9M

Profit YoY

-51.4%

EPS

$0.00

EPS estimate

$0.00

Net margin

-45.9%

Key statistics

Market cap

$8.8M

Forward P/E

0.0

P/B

0.97

Book value

$1.11

EPS (TTM)

$-0.52

52-week high

$2.39

52-week low

$0.68

50-day MA

$1.16

200-day MA

$1.12

Beta

0.51

Analyst view

Analysts rate Immuron Ltd ADR a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $3.91.

Shareholding

Institutions

1.05%

Largest institutional holders

Fund	Stake
Morgan Stanley - Brokerage Accounts	0.37%
XTX Topco Ltd	0.21%
Citadel Advisors Llc	0.17%
TWO SIGMA SECURITIES, LLC	0.13%
Rhumbline Advisers	0.09%
BNP Paribas Arbitrage, SA	0.06%
BlackRock Inc	0.00%
Jane Street Group LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immuron Ltd ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.